A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
I4D-MC-JTJH - ClinicalTrials.gov - NCT02735980
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Small Cell Lung CancerWhat the trial is testing?
PrexasertibCould I receive a Placebo?
NoEnrollment Goal
133Trial Dates
May 11, 2016 - Feb 12, 2019How long will I be in the trial?
Your participation could last up to 1 year after the last patient enrolls in the study and if you are still receiving benefit, you may continue to receive Prexasertib through a continued access program.Trial Phase
IILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo